Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults

• Päätekijät: Gulbanu Sarsenbayeva (Tekijä), Yevgeniy Volgin (Tekijä), Markhabat Kassenov (Tekijä), Timur Issagulov (Tekijä), Nikolay Bogdanov (Tekijä), Abylay Sansyzbay (Tekijä), Marina Stukova (Tekijä), Zhanna Buzitskaya (Tekijä), Ilyas Кulmagambetov (Tekijä), Timur Davlyatshin (Tekijä), Berik Khairullin (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Taylor & Francis Group, 2018-03-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background: The study was aimed at comparative evaluation of seasonal influenza vaccine RIBSP versus commercial vaccine VAXIGRIP® for immunogenicity and safety in the course of clinical trial phase II on healthy volunteers aged 18-60 years. Methods: The trial involved 150 subjects in randomized 2:1...